C0737

Cilostazol

≥98% (HPLC), powder

• 同義詞: 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 13013, OPC 21, Pletaal
• 經驗公式（希爾表示法）: C₂₀H₂₇N₅O₂
• CAS號碼: 73963-72-1
• 分子量：: 369.46
• MDL號碼: MFCD00866780
• 分類程式碼代碼: 41106305
• PubChem物質ID: 24278291
• NACRES: NA.77

屬性

• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: off-white
• 溶解度: DMSO: 10 mg/mL, clear
• 起源: Otsuka Pharma
• SMILES 字串: O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1
• InChI: 1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
• InChI 密鑰: RRGUKTPIGVIEKM-UHFFFAOYSA-N
• 基因資訊: human ... PDE3A(5139) , PDE3B(5140)

描述

一般說明

Cilostazol prevents platelet aggregation and has vasodilatory properties. It is used to treat chronic arterial disease and intermittent claudication. Cilostazol has antiproliferative effects and improves the properties of prostacyclin. It regulates cell proliferation, stimulates cyclic adenosine monophosphate (cAMP) level and induces cyclic AMP-dependent protein kinase.

應用

Cilostazol has been used:

• to reduce Madin–Darby cell line (MDCK) proliferation through c-Myc down-regulation
• in the in vitro assessment of toxin delivery in T84 intestinal epithelial cells
• to induce adenosine triphosphate (ATP) release in white adipocytes

生化／生理作用

Phosphodiesterase III (PDE3) inhibitor

特點和優勢

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Otsuka Pharma. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

安全資訊

• 象形圖: GHS08
• 訊號詞: Warning
• 危險聲明: H361d
• 防範說明: P201 - P202 - P280 - P308 + P313 - P405 - P501
• 危險分類: Repr. 2
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable
• 個人防護裝備: Eyeshields, Gloves, type N95 (US)